Generics Bulletin Explains: The Next Wave of US Humira Biosimilars

Humira ― for a long time the world’s top-selling drug, and still one of the biggest brands in the business – finally faced US biosimilar competition this year, with Amgen at the end of January launching the first of many adalimumab biosimilars approved by the US Food and Drug Administration. A multitude of other competitors are bringing further adalimumab biosimilars to the US market, as per the terms of their individual litigation settlements with originator AbbVie.

You can also download the PDF by clicking the button below

Download PDF